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Editor,
Hidradenitis suppurativa (HS) has been associated with metabolic syndrome [1-3]. Three large 
population-based studies showed a significant association of type 2 diabetes mellitus (T2DM) 
with HS [3-5]. Two meta-analyses found an increased 1.69 to 3 odds of diabetes [6-7]. In the 
present study, we aimed to compare whether the phenotype and comorbidities of HS patients 
with T2DM would differ from those without T2DM.  We reviewed retrospectively all the patients 
with HS diagnosis that attended a tertiary care hospital (Department of dermatology, Helsinki 
University Hospital, Finland) between January and December 2018. Current age (at inclusion in 
the study, in 2018), age at HS onset (when symptoms first occurred) and at HS diagnosis, family 
history, smoking, comorbidities, Hurley stages and affected body sites were inquired in each A
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patient. As the study relied on the centralized medical reports of our patients, including both 
university hospital and primary healthcare with no direct patient contact, no ethical committee 
statement was required. The data was based on analyzing patient records, which were 
anonymized before study inclusion, and the gathering of patient data for the study.
A total of 166 patients was included in this study (96 women, mean age±SD = 38.4±13.8 years).  
The prevalence of T2DM in the present cohort was 15.7% (n=26). Sixteen patients have already 
T2DM at the time of HS was diagnosis. Table 1 summarizes patients' main characteristics. Briefly, 
HS patients with T2DM had a later age at onset of HS (36.1 vs. 25.1 years, Student t-test, 
p=0.001). Among the patients for whom staging was available, patients with T2DM displayed 
more frequently Hurley stage III (58.3% [7/12] vs 12.8% [9/70], p=0.001). There were no statically 
significant differences regarding family history, body mass index, and anatomical location of HS. 
Among comorbidities, there was no difference regarding acne, pulmonary disorders (asthma, 
chronic bronchitis, sleep apnea), hypothyroidism, psychiatric disorders or inflammatory 
disorders. Patients with T2DM had higher frequencies of cardio-vascular conditions such as 
hypertension (p<0.0001), coronary disease (p=0.005), hypercholesterolemia (p=0.0007) and gout 
(p=0.001), lower limb arteriopathy (p=0.012), and past or present smoking (p=0.034). Binary 
logistic regression (taking into account gender, age, smoking, hypertension, coronary disease, 
lower limb arteriopathy, gout, dyslipidemia and overweight/obesity) showed that only 
hypertension (OR 8.4 [2.0-36.0], p=0.004) was significantly associated with T2DM among patients 
with HS.
The proportion of T2DM in our cohort was 15.7%, which is in line with ranges from the literature 
(4.5-25%) [1-7]. The link of causality between T2DM and HS is not known [1,6]. HS may promote 
T2DM through chronic inflammation with elevated TNF-, or insulin resistance may predispose 
to HS [1]. Although we found here that T2DM preceded HS diagnosis for 61% of the patients, we 
cannot confirm a temporal relationship between T2DM and HS. We did not have any T2DM time 
of diagnosis. Besides, delay of diagnosis can be long and patients may have had HS for a longer 
period [8] before even T2DM onset. Patients with T2DM seemed to have a more severe disease 
according to Hurley stages. To the best of our knowledge, severity of HS in patients with T2DM 
has never been shown. The low number of patients for which staging was available (46% of the A
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patients with T2DM) limits our results. T2DM could influence the severity of HS. We found that 
patients with T2DM was only associated with hypertension. Obesity, smoking and other cardio-
vascular comorbidities were not associated on the multivariable analysis. The main limitation of 
our study was the relatively small patient cohort and significant associations might have 
remained unrecognized due to the small patient sample. Additionally, based on the tertiary 
university hospital setting, a selection bias of severe patients should be recognized. 
Acknowledging the limits of our study, we failed to find in our cohort any specific phenotype for 
patients with T2DM and HS except a higher frequency of hypertension.  Monitoring for T2DM 
during HS remains warranted [6,7], even if the link of temporal causality between T2DM and HS 
is unclear. T2DM could be a factor of severity for HS patients, but larger comparative studies are 
needed to confirm or infirm this hypothesis.
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Table 1. Disease characteristics in HS patients with and without diabetes type 2 
 T2DM 
 
No T2DM 
 
Fisher’s exact test 
Student t-test 
P-value 
n 26 (15.7) 140 (84.3)  
Gender  
Male, n (%) 
 
16  (61.0) 
 
54 (38.0) 
 
0.033 
Mean age (SD) 53.4 (13.0) 35.7 (12.1) <0.001 
Mean age at diagnosis 
in years (SD) 
46.8 (13.7) 32.0 (11.7) <0.001 
Mean age at first 
symptoms in years 
(SD) 
36.1 (13.2) 25.1 (11.2) 0.001 
Familial history of HS 4 (40.0) 22 (42.3) 1.000 
Hurley classification    
Hurley I - 34 (48.6)  
Hurley II 5 (41.7) 27 (38.6)  
Hurley III 7 (58.3) 9 (12.8) 0.001 
Smoking    
Ever smokers 23 (95.8) 94 (70.7) 0.034 
Active smokers 11 (45.8) 71 (53.4) 0.523 
BMI at inclusion, 
kg/m2 
   
Mean (SD)  34.0 (7.3) 32.1 (8.0) 0.817 
BMI≥25 21 (80.8) 99 (70.7) 0.348 
Obesity (BMI≥30) 16 (61.5) 68 (48.6) 0.287 
Cardio-vascular    
Hypertension 16 (61.5) 21 (15) <0.00001 
Arrhythmia 3 (11.5) 6  (4.3) 0.154 
Heart infarct 4 (15.4) - 0.0005 A
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Heart insufficiency 2 (7.7) 1 (0.7) 0.064 
Low limb arteriopathy 3 (11.5) 1 (0.7) 0.012 
Stroke 1 (3.8) 2 (1.4) 0.402 
Gout 5 (19.2) 2 (1.4) 0.001 
Dyslipidemia 10 (38.5) 8 (5.7) 0.000 
Hypercholesterolemia 8 (30.8) 8 (5.7) 0.0007 
Thyroid disease 2 (7.7) 18 (12.8) 0.742 
Lung disorders    
Uniapnea 7 (26.9) 15 (10.7) 0.051 
Autoimmune and 
inflammatory 
disorders 
   
Psoriasis 2 (7.7) 11 (7.8) 1.000 
Inflammatory bowel 
disease* 
- 7 (5.0) 0.598 
Inflammatory joint 
disease** 
- 12 (8.6) 0.217 
Psychiatric diseases 7 (26.9) 53 (37.8) 0.375 
T2DM: Diabetes type 2; SD : Standard Deviation 
*Includes Crohn’s disease and ulcerative colitis 
**Includes reactive, rheumatoid, psoriatic arthritis and spondyloarthropathy  
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